(CDAX, Technology, BSL GR)



Buy EUR 170.00	(Hold) (EUR 115.00)	Value Indicators: DCF: FCF-Value Potential 23e:	171.13	Warburg ESG Risk Score: ESG Score (MSCI based): Balance Sheet Score: Market Liquidity Score:	2.7 3.0 4.0 1.0	Description: B2B digital cameras for appl such as factory, medical, tra retail.	
		Market Snapshot:	EUR m	Shareholders:		Key Figures (WRe):	2021e
		Market cap:	1,491.3	Freefloat	39.0 %	Beta:	1.1
Price	EUR 150.00	No. of shares (m):	9.9	Norbert Basler	52.0 %	Price / Book:	11.2 x
Upside	13.3 %	EV:	1,484.5	Treasury shares	5.0 %	Equity Ratio:	67 %
		Freefloat MC:	581.6	Dr. Ley (CEO)	4.0 %		
		Ø Trad. Vol. (30d):	896.82 th				

Figures temporarily burdened by bottlenecks, while demand increases further

Stated Figure	es Q3/2	021:							Comment on Figures:
FY End: 31.12. in EUR m	Q3 21	Q3 21e	Q3 20	уоу	9M 21	9M 21e	9M 20	уоу	 Although order intake increased by 137%, supply bottlenecks burdened sales growth and profitability
Sales EBT Margin EPS	49.3 3.8 7.6 % 0.29	53.7 6.5 12.2 % 0.40	40.3 5.3 13.2 % 0.40	22 % -29 % -28 %	164.6 24.5 14.9 % 1.87	168.9 27.3 16.2 % 1.97	129.2 18.1 <i>14.0 %</i> 1.37	27 % 35 % 36 %	 Sales grew by 22% yoy, but was down 19% qoq despite growing demand COGS increased as a result of high spot market prices, leading to a decline in EBT

In the third quarter, Basler's order momentum increased after an already extraordinary H1, while supply constraints on growth and profitability became more severe. Order intake, which had already increased by 65% in the first six months, gained further momentum in Q3 with a yoy growth of 137%. After nine months, order intake of EUR 238m was 85% above the previous year's figure. While this was in part driven by customers placing their orders early because of increased lead times, demand remained high across all regions and industries.

However, as a result of the supply shortages, the strong order momentum could not be translated into sales growth. Revenues grew by 23% to EUR 49.4m, below our estimate (EUR 53.7m) and Q2 (EUR 60.2m). With increased COGS due to the shortages, the gross margin of 49.1% declined compared to both Q3 20 (51.4%) and Q2 21 (54.3%). In combination with lower economies of scale, the EBT margin declined to 7.6% (Q3 20 13.2%, Q2 21 17.8%). Against this background, Basler has narrowed its target ranges for the full year and now forecasts EUR 210-220m in sales at an EBT margin of 13-15% (old: sales EUR 205-225m, EBT margin 13.0-15.5%). We have adjusted our estimates accordingly.

Despite the temporary obstacles caused by the shortages, we have become more optimistic for the medium term. Demand should remain high in 2022 and result in a notable catch-up effect as soon as the bottleneck constraints loosen. Moreover, with its transformation to a full-range supplier, Basler offers bundles built around the pylon SDK, which should increase the average unit price significantly. With the pre-configured bundles, Basler's customers should be able to shorten time-to-market and reduce development costs. By 2025, we estimate that 40% of the cameras will be sold in a bundle compared to approx. 15% today, which should result in an ASP CAGR 20-25e of 11%. We expect that the significant growth potential from this strategy will also be reflected in the new mid-term target, which we expect in the near future. We have increased our estimates for 2022 and beyond as well as our target price. After yesterday's setback, we upgrade our recommendation to Buy.


Changes in E	stimates:						Comment on Changes:
FY End: 31.12. in EUR m	2021e (old)	+ / -	2022e (old)	+ / -	2023e (old)	+ / -	 2021 estimates reduced to reflect supply chain risks For 2022 and beyond, we have increased our forecast to reflect the high
Sales	224.8	-1.9 %	257.3	7.7 %	292.4	8.7 %	demand as well as the sales potential from pre-configured bundles
EBT	34.9	-7.1 %	39.4	4.9 %	44.2	9.5 %	
EPS	2.55	-7.1 %	2.84	4.6 %	3.18	9.7 %	

170 -	FY End: 31.12.	CAGR							
160 -	in EUR m	(20-23e)	2017	2018	2019	2020	2021e	2022e	2023e
150 -	Sales	23.1 %	150.2	150.0	162.0	170.5	220.6	277.1	317.9
140 -	Change Sales yoy		54.0 %	-0.1 %	8.0 %	5.2 %	29.4 %	25.6 %	14.8 %
130 - 120 -	Gross profit margir	n	49.6 %	53.3 %	50.9 %	52.0 %	52.1 %	51.8 %	51.5 %
110 - Man	EBITDA	24.5 %	39.7	36.0	30.0	34.6	49.6	59.1	66.7
100 -	Margin		26.4 %	24.0 %	18.5 %	20.3 %	22.5 %	21.3 %	21.0 %
90 -	EBIT	34.9 %	30.5	24.8	17.0	20.1	33.2	42.1	49.2
80 -	Margin		20.3 %	16.6 %	10.5 %	11.8 %	15.1 %	15.2 %	15.5 %
70 - 60 -	Net income	32.1 %	21.6	17.0	12.9	15.1	23.7	29.7	34.9
01/21 03/21 05/21 07/21 09/21	11/21 EPS	32.2 %	2.25	1.76	1.29	1.51	2.37	2.97	3.49
Basier — CDAX (normalised)	DPS	21.8 %	0.67	0.53	0.26	0.58	0.71	0.89	1.05
Basier — CDAX (normalised)	Dividend Yield		1.6 %	0.9 %	0.6 %	1.1 %	0.5 %	0.6 %	0.7 %
Rel. Performance vs CDAX:	FCFPS		2.46	0.93	-0.97	1.38	1.23	1.50	2.09
	.6 % FCF / Market cap		5.8 %	1.6 %	-2.1 %	2.6 %	0.8 %	1.0 %	1.4 %
	EV / Sales		2.7 x	3.8 x	3.0 x	3.2 x	6.8 x	5.4 x	4.6 x
	EV/EBIIDA		10.2 x	15.7 x	16.1 x	15.6 x	30.1 x	25.1 x	22.1 x
Year to date: 94			13.2 x	22.8 x	28.4 x	26.9 x	45.0 x	35.3 x	29.9 x
Trailing 12 months: 137	.0 /0								
-									
Company events:	FCF Potential Yie	ld	7.2 %	4.1 %	2.3 %	4.8 %	2.3 %	2.7 %	3.0 %
	ROE		37.4 %	24.1 %	14.4 %	13.9 %	19.1 %	20.6 %	20.6 %
	ROCE (NOPAT)		38.4 %	23.8 %	12.7 %	12.8 %	20.2 %	22.6 %	23.8 %
	Guidance:	2021 sales El	JR 210-220m	ı, EBT margir	า 13-15%				
Year to date:94Trailing 12 months:137	2 % EV / EBITDA 3 % EV / EBIT 9 % P / E P / E adj. FCF Potential Yie ROE ROCE (NOPAT)		10.2 x 13.2 x 18.8 x 18.8 x 7.2 % 37.4 % 38.4 %	15.7 x 22.8 x 32.7 x 32.7 x 4.1 % 24.1 % 23.8 %	16.1 x 28.4 x 36.4 x 2.3 % 14.4 % 12.7 %	15.6 x 26.9 x 35.8 x 37.0 x 4.8 %	30.1 x 45.0 x 63.3 x 63.3 x 2.3 %	25.1 x 35.3 x 50.5 x 50.5 x 2.7 %	22.1 x 29.9 x 43.0 x 43.0 x 3.0 %

Analyst **Robert-Jan van der Horst** rvanderhorst@warburg-research.com +49 40 309537-290

1






Company Background

- Basler is a provider of digital cameras for production, medical applications, traffic control or retail.
- Basler focuses on the mainstream and entry-level market segments.
- Customers are mainly OEMs. The customer base is well diversified and no single customer accounts for more than 10% of revenue.
 More than 60% of revenues are direct sales.

Competitive Quality

- In terms of units Basler is the world's largest developer and manufacturer of digital cameras in a fragmented, but consolidating, market for digital cameras for B2B-applications.
- High level of vision technology expertise: Basler has one of the largest developer pools in the sector and differentiates itself with camera software competence, which accounts for more than 50% of the value creation.
- State-of-the-art product portfolio: Basler is among the first movers in digital cameras based on GigE Vision and the USB3 Vision standard. It is also an early adopter of new sensor technology.
- High service and consulting quality through direct sales and Basler's network of specialised distributors.
- Basler is present in the most important markets for vision technology in South East Asia, Europe and the US.





	Detaile	d forecas	t period				٦	ransition	al period					Term. Value
Figures in EUR m	2021e	2022e	2023e	2024e	2025e	2026e	2027e	2028e	2029e	2030e	2031e	2032e	2033e	
Sales	220.6	277.1	317.9	373.1	435.4	505.9	585.4	674.6	774.3	885.4	1,008.5	1,144.6	1,299.0	
Sales change	29.4 %	25.6 %	14.8 %	17.4 %	16.7 %	16.2 %	15.7 %	15.2 %	14.8 %	14.3 %	13.9 %	13.5 %	13.5 %	2.5 %
EBIT	33.2	42.1	49.2	57.1	67.9	78.4	90.2	103.2	117.7	133.7	151.3	171.7	194.8	
EBIT-margin	15.1 %	15.2 %	15.5 %	15.3 %	15.6 %	15.5 %	15.4 %	15.3 %	15.2 %	15.1 %	15.0 %	15.0 %	15.0 %	
Tax rate (EBT)	27.0 %	28.0 %	28.0 %	28.0 %	28.0 %	28.0 %	28.0 %	28.0 %	28.0 %	28.0 %	28.0 %	28.0 %	28.0 %	
NOPAT	24.2	30.3	35.4	41.1	48.9	56.5	64.9	74.3	84.7	96.3	108.9	123.6	140.3	
Depreciation	16.4	17.0	17.5	22.0	25.7	29.8	34.5	39.8	45.7	52.2	59.5	67.5	76.6	
in % of Sales	7.4 %	6.1 %	5.5 %	5.9 %	5.9 %	5.9 %	5.9 %	5.9 %	5.9 %	5.9 %	5.9 %	5.9 %	5.9 %	
Changes in provisions	0.8	0.0	0.0	1.5	0.6	0.6	0.7	0.8	0.9	1.0	1.1	1.2	1.4	
Change in Liquidity from														
- Working Capital	9.1	9.1	6.9	8.8	10.0	11.2	13.1	14.7	16.5	18.3	20.3	22.4	25.5	
- Capex	21.3	23.4	25.4	26.1	30.2	34.7	39.8	45.4	51.5	58.3	65.8	73.9	76.6	
Capex in % of Sales	9.7 %	8.5 %	8.0 %	7.0 %	6.9 %	6.9 %	6.8 %	6.7 %	6.7 %	6.6 %	6.5 %	6.5 %	5.9 %	
Other	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Free Cash Flow (WACC Model)	11.1	14.8	20.6	29.6	35.0	41.0	47.3	54.8	63.3	72.8	83.4	96.0	116.2	139
PV of FCF	11.2	13.9	18.1	24.2	26.7	29.2	31.4	34.0	36.6	39.3	42.0	45.1	50.9	1,300
share of PVs		2.53 %						21.10) %					76.37 %
Model parameter							Valuati	ion (m)						
Derivation of WACC:			Derivation	of Beta:			Presen	t values 20)33e	4()2			
							Termin	al Value		1,30	00			
Debt ratio	5.00 %		Financial S	Strength		0.90	Financi	al liabilitie	S	4	45			
Cost of debt (after tax)	2.1 %		Liquidity (s	hare)		1.20	Pensio	n liabilities			1			
Market return	7.00 %		Cyclicality			1.40	Hybrid	capital			0			
Risk free rate	1.50 %		Transpare	псу		1.00	Minorit	y interest			0			
			Others			0.90	Market	val. of inv	estments		0			
							Liquidit	y		4	45	No. of sha	ires (m)	9.9
WACC	7.17 %		Beta			1.08	Equity	Value		1,70	01	Value per	share (E	UR) 171.13

Sensitivity Value per Share (EUR)

	-	Terminal C	Growth								Delta EBIT	-margin					
Beta W/	ACC	1.75 %	2.00 %	2.25 %	2.50 %	2.75 %	3.00 %	3.25 %	Beta	WACC	-1.5 pp	-1.0 pp	-0.5 pp	+0.0 pp	+0.5 pp	+1.0 pp	+1.5 pp
1.27 8.2	2 %	122.89	126.34	130.08	134.15	138.60	143.47	148.84	1.27	8.2 %	118.95	124.02	129.08	134.15	139.22	144.28	149.35
1.18 7.7	7 %	136.61	140.91	145.61	150.76	156.44	162.72	169.72	1.18	7.7 %	133.81	139.46	145.11	150.76	156.42	162.07	167.72
1.13 7.4	4 %	144.44	149.27	154.57	160.41	166.87	174.06	182.11	1.13	7.4 %	142.43	148.42	154.41	160.41	166.40	172.39	178.38
1.08 7.2	2 %	153.04	158.49	164.49	171.13	178.52	186.80	196.13	1.08	7.2 %	152.03	158.39	164.76	171.13	177.50	183.86	190.23
1.03 6.9	9 %	162.52	168.69	175.52	183.12	191.63	201.23	212.13	1.03	6.9 %	162.76	169.54	176.33	183.12	189.91	196.69	203.48
0.98 6.7	7 %	173.01	180.04	187.85	196.61	206.47	217.69	230.53	0.98	6.7 %	174.83	182.09	189.35	196.61	203.87	211.13	218.38
0.89 6.2	2 %	197.75	207.00	217.44	229.30	242.89	258.62	277.04	0.89	6.2 %	204.09	212.49	220.89	229.30	237.70	246.10	254.50

• Financial liabilities are also related to the lease of the company building.

• The beta takes into consideration the low liquidity of the share.

• The structural growth of the vision technology market forms the basis of Basler's revenue increases.



Free Cash Flow Value Potential

Warburg Research's valuation tool "FCF Value Potential" reflects the ability of the company to generate sustainable free cash flows. It is based on the "FCF potential" - a FCF "ex growth" figure - which assumes unchanged working capital and pure maintenance capex. A value indication is derived via the perpetuity of a given year's "FCF potential" with consideration of the weighted costs of capital. The fluctuating value indications over time add a timing element to the DCF model (our preferred valuation tool).

in EUR m	2017	2018	2019	2020	2021e	2022e	2023e
Net Income before minorities	21.6	17.0	12.9	15.1	23.7	29.7	34.9
+ Depreciation + Amortisation	9.2	11.1	12.9	14.5	16.4	17.0	17.5
 Net Interest Income 	-0.7	-0.3	-0.1	0.4	-0.8	-0.8	-0.8
 Maintenance Capex 	2.8	2.9	5.0	0.0	6.6	8.3	9.5
+ Other	0.3	-2.1	-10.0	-3.3	0.3	0.3	0.3
= Free Cash Flow Potential	29.0	23.4	10.9	26.0	34.5	39.5	43.9
FCF Potential Yield (on market EV)	7.2 %	4.1 %	2.3 %	4.8 %	2.3 %	2.7 %	3.0 %
WACC	7.17 %	7.17 %	7.17 %	7.17 %	7.17 %	7.17 %	7.17 %
= Enterprise Value (EV)	402.6	564.9	482.6	539.5	1,493.1	1,485.7	1,474.3
= Fair Enterprise Value	404.3	326.5	152.2	362.0	481.4	551.1	612.4
- Net Debt (Cash)	-2.8	-2.8	-2.8	-2.8	-8.8	-16.2	-27.6
- Pension Liabilities	1.1	1.1	1.1	1.1	1.9	1.9	1.9
- Other	0.0	0.0	0.0	0.0	0.0	0.0	0.0
 Market value of minorities 	0.0	0.0	0.0	0.0	0.0	0.0	0.0
+ Market value of investments	0.0	0.0	0.0	0.0	0.0	0.0	0.0
= Fair Market Capitalisation	406.0	328.2	153.9	363.7	488.3	565.4	638.2
Number of shares, average	9.6	9.6	9.9	10.0	10.0	10.0	10.0
= Fair value per share (EUR)	42.18	34.04	15.48	36.35	48.83	56.54	63.82
premium (-) / discount (+) in %					-67.4 %	-62.3 %	-57.5 %
Sensitivity Fair value per Share (El	JR)						
10	.17 % 28.85	23.33	10.97	25.85	34.83	40.52	46.02
9	.17 % 31.97	25.85	12.15	28.64	38.55	44.78	50.76
	.17 % 35.86	28.99	13.61	32.13	43.19	50.09	56.65
	.17 % 40.84	33.01	15.48	36.58	49.11	56.87	64.19
	.17 % 47.43	38.33	17.96	42.48	56.95	65.85	74.17
	.17 % 56.56	45.71	21.40	50.66	67.83	78.30	88.01
4	.17 % 70.08	56.62	26.49	62.76	83.92	96.72	108.48

Adjustment of the capitalised R&D impact

• The capex requirements for machinery and plant are low.



Valuation							
	2017	2018	2019	2020	2021e	2022e	2023e
Price / Book	6.2 x	7.4 x	4.5 x	4.7 x	11.2 x	9.6 x	8.2 x
Book value per share ex intangibles	4.22	3.57	4.10	5.00	6.20	7.74	9.55
EV / Sales	2.7 x	3.8 x	3.0 x	3.2 x	6.8 x	5.4 x	4.6 x
EV / EBITDA	10.2 x	15.7 x	16.1 x	15.6 x	30.1 x	25.1 x	22.1 x
EV / EBIT	13.2 x	22.8 x	28.4 x	26.9 x	45.0 x	35.3 x	29.9 x
EV / EBIT adj.*	13.2 x	22.8 x	28.4 x	26.9 x	45.0 x	35.3 x	29.9 x
P / FCF	17.2 x	61.9 x	n.a.	39.1 x	128.2 x	105.0 x	75.4 x
P/E	18.8 x	32.7 x	36.4 x	35.8 x	63.3 x	50.5 x	43.0 x
P / E adj.*	18.8 x	32.7 x	36.4 x	37.0 x	63.3 x	50.5 x	43.0 x
Dividend Yield	1.6 %	0.9 %	0.6 %	1.1 %	0.5 %	0.6 %	0.7 %
FCF Potential Yield (on market EV)	7.2 %	4.1 %	2.3 %	4.8 %	2.3 %	2.7 %	3.0 %
*Adjustments made for: -							

Company Specific Items

	2017	2018	2019	2020	2021e	2022e	2023e
revenue per employee	298.02	249.59	234.34	211.23	211.23	211.23	211.23
Camera Units	430,000	399,000	360,000	450,000	544,500	658,845	797,202
Book to Bill	1.0	1.0	1.0	1.0	1.0	1.0	1.0
ASP	349	376	450	379	405	421	399




Consolidated profit and loss

In EUR m Sales Change Sales yoy COGS Gross profit Gross margin	2017 150.2 54.0 % 75.7 74.5 49.6 % 10.8 19.6	2018 150.0 -0.1 % 70.1 79.9 53.3 %	2019 162.0 8.0 % 79.5 82.4	2020 170.5 5.2 % 81.7 88.7	2021e 220.6 29.4 % 105.6	2022e 277.1 25.6 % 133.5	2023e 317.9 14.8 % 154.2
Change Sales yoy COGS Gross profit	54.0 % 75.7 74.5 49.6 % 10.8	-0.1 % 70.1 79.9	8.0 % 79.5 82.4	5.2 % 81.7	29.4 % 105.6	25.6 %	14.8 %
COGS Gross profit	75.7 74.5 49.6 % 10.8	70.1 79.9	79.5 82.4	81.7	105.6		-
Gross profit	74.5 49.6 % 10.8	79.9	82.4			133.5	
•	49.6 % 10.8		-		114.9	143.5	163.7
			50.9 %	52.0 %	52.1 %	51.8 %	51.5 %
Research and development	10.6	18.8	17.9	21.7	29.4	36.2	40.7
Sales and marketing	19.0	23.0	31.5	30.6	34.5	41.5	46.2
Administration expenses	13.1	12.7	15.8	17.4	18.2	22.9	26.7
Other operating expenses	1.2	1.4	1.0	0.2	0.6	1.4	1.6
Other operating income	0.7	0.8	0.8	1.1	1.0	0.6	0.7
Unfrequent items	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBITDA	39.7	36.0	30.0	34.6	49.6	59.1	66.7
Margin	26.4 %	24.0 %	18.5 %	20.3 %	22.5 %	21.3 %	21.0 %
Depreciation of fixed assets	3.6	3.2	5.0	6.3	5.0	5.2	5.4
EBITA	36.1	32.8	25.0	28.3	44.6	53.9	61.3
Amortisation of intangible assets	5.6	7.9	8.0	8.2	11.4	11.8	12.1
Goodwill amortisation	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBIT	30.5	24.8	17.0	20.1	33.2	42.1	49.2
Margin	20.3 %	16.6 %	10.5 %	11.8 %	15.1 %	15.2 %	15.5 %
EBIT adj.	30.5	24.8	17.0	20.1	33.2	42.1	49.2
Interest income	0.3	0.2	1.0	1.1	0.2	0.2	0.2
Interest expenses	1.0	0.5	1.1	0.8	1.0	1.0	1.0
Other financial income (loss)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBT	29.8	24.5	16.9	20.4	32.5	41.3	48.4
Margin	19.8 %	16.3 %	10.4 %	12.0 %	14.7 %	14.9 %	15.2 %
Total taxes	8.2	7.5	4.0	5.3	8.8	11.6	13.6
Net income from continuing operations	21.6	17.0	12.9	15.1	23.7	29.7	34.9
Income from discontinued operations (net of tax)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income before minorities	21.6	17.0	12.9	15.1	23.7	29.7	34.9
Minority interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income	21.6	17.0	12.9	15.1	23.7	29.7	34.9
Margin	14.4 %	11.3 %	7.9 %	8.9 %	10.7 %	10.7 %	11.0 %
Number of shares, average	9.6	9.6	9.9	10.0	10.0	10.0	10.0
EPS	2.25	1.76	1.29	1.51	2.37	2.97	3.49
EPS adj.	2.25	1.76	1.29	1.46	2.37	2.97	3.49
*Adjustments made for:							


Guidance: 2021 sales EUR 210-220m, EBT margin 13-15%

Financial Ratios

	2017	2018	2019	2020	2021e	2022e	2023e
Total Operating Costs / Sales	29.3 %	36.7 %	40.4 %	40.3 %	37.0 %	36.6 %	36.0 %
Operating Leverage	2.8 x	140.8 x	-3.9 x	3.4 x	2.2 x	1.0 x	1.1 x
EBITDA / Interest expenses	40.5 x	78.2 x	28.3 x	45.0 x	52.2 x	59.1 x	66.7 x
Tax rate (EBT)	27.4 %	30.6 %	23.9 %	26.0 %	27.0 %	28.0 %	28.0 %
Dividend Payout Ratio	30.0 %	30.0 %	20.1 %	38.4 %	30.0 %	30.0 %	30.0 %
Sales per Employee	298,018	249,589	189,872	199,835	242,373	288,594	331,166



Performance per Share



COMMENT Published 05.11.2021


Consolidated balance .



In EUR m	2017	2018	2019	2020	2021e	2022e	2023e
Assets							
Goodwill and other intangible assets	24.6	40.8	62.0	64.8	71.4	78.6	86.5
thereof other intangible assets	1.5	6.5	16.8	31.0	33.1	35.3	37.6
thereof Goodwill	3.1	12.7	27.5	27.5	27.5	27.5	27.5
Property, plant and equipment	21.3	22.5	30.6	29.3	27.6	26.8	26.8
Financial assets	1.7	1.7	4.6	2.2	2.2	2.2	2.2
Other long-term assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Fixed assets	47.5	65.1	97.2	96.3	101.2	107.6	115.5
Inventories	20.8	21.0	20.9	20.0	31.5	39.0	44.8
Accounts receivable	11.1	18.2	19.4	19.5	17.5	22.8	26.1
Liquid assets	36.0	31.8	35.2	47.9	43.0	50.4	61.9
Other short-term assets	2.2	2.8	8.5	6.5	6.5	6.5	6.5
Current assets	70.2	73.9	84.0	93.8	98.5	118.7	139.2
Total Assets	117.7	139.0	181.2	190.1	199.7	226.3	254.8
Liabilities and shareholders' equity							
Subscribed capital	3.2	3.2	10.0	10.0	10.0	10.0	10.0
Capital reserve	3.1	5.3	22.4	22.6	22.6	22.6	22.6
Retained earnings	59.0	66.5	74.8	87.1	110.8	140.5	175.4
Other equity components	0.3	0.5	-4.2	-4.8	-10.0	-17.1	-26.0
Shareholders' equity	65.6	75.5	103.0	114.9	133.4	156.0	182.0
Minority interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total equity	65.6	75.5	103.0	114.9	133.4	156.0	182.0
Provisions	7.2	8.3	8.2	9.4	10.8	11.1	11.4
thereof provisions for pensions and similar obligations	1.4	1.2	0.9	1.1	1.9	1.9	1.9
Financial liabilities (total)	29.3	39.8	50.0	45.1	34.2	34.2	34.2
Short-term financial liabilities	0.0	1.8	5.3	4.1	4.1	4.1	4.1
Accounts payable	10.1	7.4	10.6	11.1	11.5	15.2	17.4
Other liabilities	5.5	7.9	9.4	9.7	9.7	9.7	9.7
Liabilities	52.1	63.4	78.2	75.2	66.3	70.2	72.8
Total liabilities and shareholders' equity	117.7	139.0	181.2	190.1	199.7	226.3	254.8

Financial Ratios

	2017	2018	2019	2020	2021e	2022e	2023e
Efficiency of Capital Employment							
Operating Assets Turnover	3.5 x	2.8 x	2.7 x	3.0 x	3.4 x	3.8 x	4.0 x
Capital Employed Turnover	2.5 x	1.8 x	1.4 x	1.5 x	1.7 x	2.0 x	2.0 x
ROA	45.5 %	26.1 %	13.2 %	15.7 %	23.4 %	27.6 %	30.2 %
Return on Capital							
ROCE (NOPAT)	38.4 %	23.8 %	12.7 %	12.8 %	20.2 %	22.6 %	23.8 %
ROE	37.4 %	24.1 %	14.4 %	13.9 %	19.1 %	20.6 %	20.6 %
Adj. ROE	37.4 %	24.1 %	14.4 %	13.4 %	19.1 %	20.6 %	20.6 %
Balance sheet quality							
Net Debt	-5.3	9.1	15.7	-1.7	-6.9	-14.3	-25.7
Net Financial Debt	-6.7	8.0	14.9	-2.8	-8.8	-16.2	-27.6
Net Gearing	-8.1 %	12.1 %	15.3 %	-1.5 %	-5.2 %	-9.1 %	-14.1 %
Net Fin. Debt / EBITDA	n.a.	22.2 %	49.6 %	n.a.	n.a.	n.a.	n.a.
Book Value / Share	6.8	7.8	10.3	11.5	13.3	15.6	18.2
Book value per share ex intangibles	4.2	3.6	4.1	5.0	6.2	7.7	9.5



Consolidated cash flow statement



In EUR m	2017	2018	2019	2020	2021e	2022e	2023e
Net income	21.6	17.0	12.9	15.1	23.7	29.7	34.9
Depreciation of fixed assets	3.6	3.2	5.0	6.3	5.0	5.2	5.4
Amortisation of goodwill	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Amortisation of intangible assets	5.6	7.9	8.0	8.2	11.4	11.8	12.1
Increase/decrease in long-term provisions	0.0	0.0	-0.1	1.1	0.8	0.0	0.0
Other non-cash income and expenses	2.3	1.7	-3.7	5.1	0.3	0.5	0.5
Cash Flow before NWC change	33.1	29.9	22.1	35.9	41.2	47.2	52.9
Increase / decrease in inventory	-5.8	2.2	0.1	0.9	-11.5	-7.5	-5.8
Increase / decrease in accounts receivable	-0.5	-6.4	-1.1	-0.1	2.0	-5.3	-3.3
Increase / decrease in accounts payable	5.3	-4.5	3.2	0.5	0.4	3.7	2.2
Increase / decrease in other working capital positions	-0.3	5.8	0.5	0.1	1.4	0.3	0.3
Increase / decrease in working capital (total)	-1.3	-2.9	2.7	1.5	-7.6	-8.8	-6.6
Net cash provided by operating activities [1]	31.8	27.0	24.7	37.3	33.6	38.4	46.3
nvestments in intangible assets	-4.0	-13.6	-29.3	-20.6	-18.0	-19.0	-20.0
nvestments in property, plant and equipment	-4.1	-4.5	-5.1	-2.7	-3.3	-4.4	-5.4
Payments for acquisitions	-1.9	-7.7	0.0	0.0	0.0	0.0	0.0
Financial investments	0.0	0.0	0.0	0.0	0.0	0.0	0.0
ncome from asset disposals	0.2	0.1	0.1	0.2	0.1	0.1	0.1
Net cash provided by investing activities [2]	-9.8	-25.7	-34.2	-23.3	-21.2	-23.3	-25.3
Change in financial liabilities	-1.3	4.8	-1.8	2.3	-10.8	0.0	0.0
Dividends paid	-2.4	-6.5	-5.1	-2.6	-5.8	-7.1	-8.9
Purchase of own shares	-0.7	-3.3	20.8	0.0	0.0	0.0	0.0
Capital measures	0.0	0.0	0.0	-0.2	0.0	0.0	0.0
Other	-1.1	-0.5	-1.0	-0.8	-0.6	-0.6	-0.6
Net cash provided by financing activities [3]	-5.4	-5.5	13.0	-1.3	-17.2	-7.7	-9.5
Change in liquid funds [1]+[2]+[3]	16.6	-4.2	3.5	12.7	-4.9	7.4	11.5
Effects of exchange-rate changes on cash	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Cash and cash equivalent at end of period	36.0	31.8	35.3	47.9	43.0	50.4	61.9

Financial Ratios


	2017	2018	2019	2020	2021e	2022e	2023e
Cash Flow							
FCF	23.7	9.0	-9.6	13.8	12.3	15.0	20.9
Free Cash Flow / Sales	15.8 %	6.0 %	-5.9 %	8.1 %	5.6 %	5.4 %	6.6 %
Free Cash Flow Potential	29.0	23.4	10.9	26.0	34.5	39.5	43.9
Free Cash Flow / Net Profit	109.5 %	52.7 %	-74.6 %	91.6 %	51.8 %	50.4 %	59.9 %
Interest Received / Avg. Cash	1.0 %	0.5 %	2.9 %	2.7 %	0.4 %	0.4 %	0.4 %
Interest Paid / Avg. Debt	3.7 %	1.3 %	2.4 %	1.6 %	2.4 %	2.9 %	2.9 %
Management of Funds							
Investment ratio	5.4 %	12.0 %	21.2 %	13.7 %	9.7 %	8.5 %	8.0 %
Maint. Capex / Sales	1.9 %	1.9 %	3.1 %	0.0 %	3.0 %	3.0 %	3.0 %
Capex / Dep	88.3 %	161.8 %	265.4 %	160.6 %	129.9 %	137.8 %	145.2 %
Avg. Working Capital / Sales	13.5 %	17.9 %	19.0 %	17.1 %	14.9 %	15.2 %	15.7 %
Trade Debtors / Trade Creditors	109.5 %	246.9 %	183.1 %	175.9 %	152.2 %	150.0 %	150.0 %
Inventory Turnover	3.6 x	3.3 x	3.8 x	4.1 x	3.4 x	3.4 x	3.4 x
Receivables collection period (days)	27	44	44	42	29	30	30
Payables payment period (days)	49	39	49	49	40	42	41
Cash conversion cycle (Days)	79	115	91	82	98	95	95

Free Cash Flow Generation

CAPEX and Cash Flow



Working Capital



COMMENT

Published 05.11.2021

8



LEGAL DISCLAIMER

This research report ("investment recommendation") was prepared by the Warburg Research GmbH, a fully owned subsidiary of the M.M.Warburg & CO (AG & Co.) KGaA and is passed on by the M.M.Warburg & CO (AG & Co.) KGaA. It is intended solely for the recipient and may not be passed on to another company without their prior consent, regardless of whether the company is part of the same corporation or not. It contains selected information and does not purport to be complete. The investment recommendation is based on publicly available information and data ("information") believed to be accurate and complete. Warburg Research GmbH neither examines the information for accuracy and completeness, nor guarantees its accuracy and completeness. Possible errors or incompleteness of the information do not constitute grounds for liability of M.M.Warburg & CO (AG & Co.) KGaA or Warburg Research GmbH for damages of any kind whatsoever, and M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are not liable for indirect and/or direct and/or consequential damages. In particular, neither M.M.Warburg & CO (AG & Co.) KGaA nor Warburg Research GmbH are liable for the statements, plans or other details contained in these investment recommendations concerning the examined companies, their affiliated companies, strategies, economic situations, market and competitive situations, regulatory environment, etc. Although due care has been taken in compiling this investment recommendation, it cannot be excluded that it is incomplete or contains errors. M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH, their shareholders and employees are not liable for the accuracy and completeness of the statements, estimations and the conclusions derived from the information contained in this investment recommendation. Provided a investment recommendation is being transmitted in connection with an existing contractual relationship, i.e. financial advisory or similar services, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH shall be restricted to gross negligence and wilful misconduct. In case of failure in essential tasks, M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are liable for normal negligence. In any case, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH is limited to typical, expectable damages. This investment recommendation does not constitute an offer or a solicitation of an offer for the purchase or sale of any security. Partners, directors or employees of M.M.Warburg & CO (AG & Co.) KGaA, Warburg Research GmbH or affiliated companies may serve in a position of responsibility, i.e. on the board of directors of companies mentioned in the report. Opinions expressed in this investment recommendation are subject to change without notice. All rights reserved.

COPYRIGHT NOTICE

This work including all its parts is protected by copyright. Any use beyond the limits provided by copyright law without permission is prohibited and punishable. This applies, in particular, to reproductions, translations, microfilming, and storage and processing on electronic media of the entire content or parts thereof.

DISCLOSURE ACCORDING TO §85 OF THE GERMAN SECURITIES TRADING ACT (WPHG), MAR AND MIFID II INCL. COMMISSION DELEGATED REGULATION (EU) 2016/958 AND (EU) 2017/565

The valuation underlying the investment recommendation for the company analysed here is based on generally accepted and widely used methods of fundamental analysis, such as e.g. DCF Model, Free Cash Flow Value Potential, NAV, Peer Group Comparison or Sum of the Parts Model (see also <u>http://www.mmwarburg.de/disclaimer/disclaimer.htm#Valuation</u>). The result of this fundamental valuation is modified to take into consideration the analyst's assessment as regards the expected development of investor sentiment and its impact on the share price.

Independent of the applied valuation methods, there is the risk that the price target will not be met, for instance because of unforeseen changes in demand for the company's products, changes in management, technology, economic development, interest rate development, operating and/or material costs, competitive pressure, supervisory law, exchange rate, tax rate etc. For investments in foreign markets and instruments there are further risks, generally based on exchange rate changes or changes in political and social conditions.

This commentary reflects the opinion of the relevant author at the point in time of its compilation. A change in the fundamental factors underlying the valuation can mean that the valuation is subsequently no longer accurate. Whether, or in what time frame, an update of this commentary follows is not determined in advance.

Additional internal and organisational arrangements to prevent or to deal with conflicts of interest have been implemented. Among these are the spatial separation of Warburg Research GmbH from M.M.Warburg & CO (AG & Co.) KGaA and the creation of areas of confidentiality. This prevents the exchange of information, which could form the basis of conflicts of interest for Warburg Research GmbH in terms of the analysed issuers or their financial instruments.

The analysts of Warburg Research GmbH do not receive a gratuity – directly or indirectly – from the investment banking activities of M.M.Warburg & CO (AG & Co.) KGaA or of any company within the Warburg-Group.

All prices of financial instruments given in this investment recommendation are the closing prices on the last stock-market trading day before the publication date stated, unless another point in time is explicitly stated.

M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are subject to the supervision of the Federal Financial Supervisory Authority, BaFin. M.M.Warburg & CO (AG & Co.) KGaA is additionally subject to the supervision of the European Central Bank (ECB).



SOURCES

All data and consensus estimates have been obtained from FactSet except where stated otherwise.

The **Warburg ESG Risk Score** is based on information © 2020 MSCI ESG Research LLC. Reproduced by permission. Although Warburg Research's information providers, including without limitation, MSCI ESG Research LLC and its affiliates (the "ESG Parties"), obtain information (the "Information") from sources they consider reliable, none of the ESG Parties warrants or guarantees the originality, accuracy and/or completeness, of any data herein and expressly disclaim all express or implied warranties, including those of merchantability and fitness for a particular purpose. The Information may only be used for your internal use, may not be reproduced or redisseminated in any form and may not be used as a basis for, or a component, of any financial instruments or products indices. Further, none of the Information can in and of itself be used to determine which securities to buy or sell or when to buy or sell them. None of the ESG Parties shall have any liability for any errors or omissions in connection with any data herein, or any liability for any direct, indirect, special, punitive, consequential or any other damage (including lost profits) even if notified of the possibility.

-4-



Additional information for clients in the United States

1. This research report (the "Report") is a product of Warburg Research GmbH, Germany, a fully owned subsidiary of M.M.Warburg & CO (AG & Co.)

KGaA, Germany (in the following collectively "Warburg"). Warburg is the employer of the research analyst(s), who have prepared the Report. The research analyst(s) reside outside the United States and are not associated persons of any U.S. regulated broker-dealer and therefore are not subject to the supervision of any U.S. regulated broker-dealer.

2. The Report is provided in the United States for distribution solely to "major U.S. institutional investors" under Rule 15a-6 of the U.S. Securities Exchange Act of 1934 by CIC.

3. CIC (Crédit Industriel et Commercial) and M.M. Warburg & CO have concluded a Research Distribution Agreement that gives CIC Market Solutions exclusive distribution in France, the US and Canada of the Warburg Research GmbH research product.

4. The research reports are distributed in the United States of America by CIC ("CIC") pursuant to a SEC Rule 15a-6 agreement with CIC Market Solutions Inc ("CICI"), a U.S. registered broker-dealer and a related company of CIC, and are distributed solely to persons who qualify as "Major U.S. Institutional Investors" as defined in SEC Rule 15a-6 under the Securities Exchange Act of 1934.

5. Any person who is not a Major U.S. Institutional Investor must not rely on this communication. The delivery of this research report to any person in the United States of America is not a recommendation to effect any transactions in the securities discussed herein, or an endorsement of any opinion expressed herein.

Reference in accordance with section 85 of the German Securities Trading Act (WpHG) and Art. 20 MAR regarding possible conflicts of interest with companies analysed:

- -1- Warburg Research, or an affiliated company, or an employee of one of these companies responsible for the compilation of the research, hold a **share of more than 5%** of the equity capital of the analysed company.
- Warburg Research, or an affiliated company, within the last twelve months participated in the management of a consortium for an issue in
 -2- the course of a public offering of such financial instruments, which are, or the issuer of which is, the subject of the investment recommendation.
- -3- Companies affiliated with Warburg Research manage financial instruments, which are, or the issuers of which are, subject of the investment recommendation, in a market based on the provision of buy or sell contracts.

MMWB, Warburg Research, or an affiliated company, reached an agreement with the issuer to provide **investment banking and/or investment services** and the relevant agreement was in force in the last 12 months or there arose for this period, based on the relevant agreement, the obligation to provide or to receive a service or compensation - provided that this disclosure does not result in the disclosure of

- confidential business information.
- -5- The company compiling the analysis or an affiliated company had reached an **agreement on the compilation of the investment** recommendation with the analysed company.
- -6a- Warburg Research, or an affiliated company, holds a **net long position of more than 0.5%** of the total issued share capital of the analysed company.
- -6b- Warburg Research, or an affiliated company, holds a **net short position of more than 0.5%** of the total issued share capital of the analysed company.
- -6c- The issuer holds shares of more than 5% of the total issued capital of Warburg Research or an affiliated company.
- -7- The company preparing the analysis as well as its affiliated companies and employees have **other important interests** in relation to the analysed company, such as, for example, the exercising of mandates at analysed companies.

This report has been made accessible to the company analysed.

Company	Disclosure	Link to the historical price targets and rating changes (last 12 months)
Basler	3, 5	http://www.mmwarburg.com/disclaimer/disclaimer_en/DE0005102008.htm



INVESTMENT RECOMMENDATION

Investment recommendation: expected direction of the share price development of the financial instrument up to the given <u>price target</u> in the opinion of the analyst who covers this financial instrument.

-B-	Buy:	The price of the analysed financial instrument is expected to rise over the next 12 months.			
-H-	Hold:	The price of the analysed financial instrument is expected to remain mostly flat over the next 12 months.			
-S-	Sell:	The price of the analysed financial instrument is expected to fall over the next 12 months.			
"_"	Rating suspended:	The available information currently does not permit an evaluation of the company.			

WARBURG RESEARCH GMBH - ANALYSED RESEARCH UNIVERSE BY RATING

Rating	Number of stocks	% of Universe
Buy	148	69
Hold	59	27
Sell	6	3
Rating suspended	2	1
Total	215	100

WARBURG RESEARCH GMBH – ANALYSED RESEARCH UNIVERSE BY RATING ...

... taking into account only those companies which were provided with major investment services in the last twelve months.

Rating	Number of stocks	% of Universe
Buy	48	81
Hold	9	15
Sell	0	0
Rating suspended	2	3
Total	59	100

PRICE AND RATING HISTORY BASLER AS OF 05.11.2021



Markings in the chart show rating changes by Warburg Research GmbH in the last 12 months. Every marking details the date and closing price on the day of the rating change.

EQUITIES

Matthias Rode Head of Equities

RESEARCH

Michael Heider Head of Research Henner Rüschmeier Head of Research Stefan Augustin Cap. Goods, Engineering Jan Bauer Renewables Jonas Blum Telco, Media, Construction **Christian Cohrs** Industrials & Transportation Dr. Christian Ehmann BioTech. Life Science Felix Ellmann Software, IT Jörg Philipp Frey Retail, Consumer Goods Marius Fuhrberg **Financial Services** Mustafa Hidir Automobiles, Car Suppliers Philipp Kaiser Real Estate

INSTITUTIONAL EQUITY SALES

+49 40 309537-280 mheider@warburg-research.com +49 40 309537-270 hrueschmeier@warburg-research.com +49 40 309537-168 saugustin@warburg-research.com +49 40 309537-155 jbauer@warburg-research.com +49 40 309537-240 jblum@warburg-research.com +49 40 309537-175 ccohrs@warburg-research.com +49 40 309537-167 cehmann@warburg-research.com +49 40 309537-120 fellmann@warburg-research.com +49 40 309537-258 jfrey@warburg-research.com +49 40 309537-185 mfuhrberg@warburg-research.com +49 40 309537-230 mhidir@warburg-research.com +49 40 309537-260 pkaiser@warburg-research.com

+49 40 3282-2678

mrode@mmwarburg.com

+49 40 3282-2660 mniemann@mmwarburg.com +49 69 5050-7400 kschilling@mmwarburg.com +49 40 3282-2665 tbeckmann@mmwarburg.com +49 69 5050-7411 lbogdanova@mmwarburg.com +49 69 5050-7415 jbuchmueller@mmwarburg.com +49 40 3282-2669 aeschweiler@mmwarburg.com +49 40 3282-2696 mfritsch@mmwarburg.com

SALES TRADING

Marc Niemann

Klaus Schilling

Tim Beckmann

Lea Bogdanova

Jens Buchmüller

Scandinavia, Austria

United Kingdom, Ireland

Alexander Eschweiler

Germany, Luxembourg

Matthias Fritsch

United Kingdom

United Kingdom

Head of Equity Sales. Germany

Head of Equity Sales, Germany

 Oliver Merckel
 +49 40 3282-2634

 Head of Sales Trading
 omerckel@mmwarburg.com

 Elyaz Dust
 +49 40 3282-2702

 Sales Trading
 edust@mmwarburg.com

 Michael Ilgenstein
 +49 40 3282-2700

 Sales Trading
 edust@mmwarburg.com

 Michael Ilgenstein
 +49 40 3282-2700

 Sales Trading
 milgenstein@mmwarburg.com

MACRO RESEARCH

Carsten Klude +49 40 3282-2572 Dr. Christian Jasperneite Investment Strategy cklude@mmwarburg.com Macro Research Our research can be found under: Refinitiv Warburg Research research.mmwarburg.com/en/index.html Bloomberg RESP MMWA GO Capital IQ FactSet www.factset.com For access please contact:

Andrea Schaper

Sales Assistance

+49 40 3282-2632 Kerstin Muthig aschaper@mmwarburg.com Sales Assistance

Kerstin Muthig

Thilo Kleibauer Retail, Consumer Goods Eggert Kuls Engineering Andreas Pläsier Banks, Financial Services Malte Schaumann Technology **Oliver Schwarz** Chemicals, Agriculture Simon Stippig Real Estate Cansu Tatar Cap. Goods. Engineering Marc-René Tonn Automobiles, Car Suppliers Robert-Jan van der Horst Technology Andreas Wolf Software, IT

Maximilian Martin

Christopher Seedorf

Austria, Poland

Sophie Hauer Roadshow/Marketing

Juliane Niemann

Roadshow/Marketing

Marcel Magiera

Bastian Quast

Sales Trading

Sales Trading

Sales Trading

Jörg Treptow

Switzerland

+49 40 309537-257 tkleibauer@warburg-research.com +49 40 309537-256 ekuls@warburg-research.com +49 40 309537-246 aplaesier@warburg-research.com +49 40 309537-170 mschaumann@warburg-research.com +49 40 309537-250 oschwarz@warburg-research.com +49 40 309537-265 sstippig@warburg-research.com +49 40 309537-248 ctatar@warburg-research.com +49 40 309537-259 mtonn@warburg-research.com +49 40 309537-290 rvanderhorst@warburg-research.com +49 40 309537-140 awolf@warburg-research.com

> +49 69 5050-7413 mmartin@mmwarburg.com +49 40 3282-2695 cseedorf@mmwarburg.com

> +49 69 5050-7417 shauer@mmwarburg.com +49 40 3282-2694 jniemann@mmwarburg.com

+49 40 3282-2662 mmagiera@mmwarburg.com +49 40 3282-2701 bquast@mmwarburg.com +49 40 3282-2658 jtreptow@mmwarburg.com

+49 40 3282-2439 cjasperneite@mmwarburg.com

www.refinitiv.com www.capitaliq.com

+49 40 3282-2703 kmuthig@mmwarburg.com

